Introduction {#s1}
============

Membrane-associated RING-CH (MARCH) 8 is one of 11 members of the MARCH family of RING-finger E3 ubiquitin ligases, which consist of an N-terminal cytoplasmic tail (CT) domain containing a C4HC3 RING finger (RING-CH finger) motif, two transmembrane (TM) domains, between which a short ectodomain is located, and a C-terminal CT domain ([@bib2]; [@bib7]). MARCH8 downregulates a variety of cellular transmembrane proteins, such as MHC-II ([@bib13]), CD86 ([@bib16]), CD81 ([@bib3]), CD44 ([@bib5]), TRAIL receptor 1 ([@bib17]), CD98 ([@bib5]), IL-1 receptor accessory protein ([@bib4]), and transferrin receptor ([@bib6]). We have recently reported that MARCH8 reduces HIV-1 infectivity by downregulating HIV-1 envelope glycoproteins (Env) from the cell surface, resulting in a reduced incorporation of Env into virions ([@bib14]). Intriguingly, vesicular stomatitis virus G-glycoprotein (VSV-G) was even more sensitive to the inhibitory effect of MARCH8. In the case of HIV-1 Env, it is retained intracellularly without degradation after cell-surface downregulation. In contrast, VSV-G is not only downregulated from the cell surface but also undergoes lysosomal degradation by MARCH8 ([@bib14]). In this regard, we hypothesized that VSV-G, whose cytoplasmic tail is lysine-rich (5 out of 29 amino acids), could be readily ubiquitinated by the E3 ubiquitin ligase MARCH8 and therefore undergo lysosomal degradation, whereas HIV-1 Env carries only two lysines (out of 151 amino acids) in its cytoplasmic tail and may rarely undergo degradation after being trapped by MARCH8. In this study, we created lysine mutants of both HIV-1 Env and VSV-G, together with newly generated MARCH8 mutants to explore the hypothesis described above. The results with these mutants show that MARCH8 targets HIV-1 Env and VSV-G by two different inhibitory mechanisms.

Results and discussion {#s2}
======================

We have recently reported that MARCH8 inhibits lentiviral infection by reducing virion incorporation of both HIV-1 Env and VSV-G in a RING-CH domain-dependent manner. Because the RING-CH domain is known to be essential for the E3 ubiquitin ligase activity of MARCH8, we asked whether these envelope glycoproteins are susceptible to MARCH8-mediated ubiquitination. To investigate this, we first created the VSV-G mutant CT5K/R in which five arginine residues were introduced in place of cytoplasmic lysine residues that could be ubiquitination targets ([Figure 1A](#fig1){ref-type="fig"}, upper). We also generated the HIV-1 Env gp41 mutant CT2K/R harboring two arginines in place of the cytoplasmic lysines ([Figure 1A](#fig1){ref-type="fig"}, lower). Then, we prepared HIV-1 luciferase reporter viruses pseudotyped with the mutant envelope glycoproteins (VSV-G CT5K/R and HIV-1 Env CT2K/R) from 293T cells transiently expressing MARCH8, and compared their viral infectivity with that of control viruses pseudotyped with wild-type (WT) envelope glycoproteins. The infectivity of viruses harboring either VSV-G CT5K/R or HIV-1 gp41 Env CT2K/R was almost comparable to WT-enveloped viruses ([Figure 1B and C](#fig1){ref-type="fig"}). As expected, the virus pseudotyped with VSV-G CT5K/R was completely resistant to MARCH8 ([Figure 1B](#fig1){ref-type="fig"}). In contrast, the HIV-1 Env CT2K/R-pseudotyped virus was still susceptible to the inhibitory effect of MARCH8 ([Figure 1C](#fig1){ref-type="fig"}). Consistent with these results, immunofluorescence staining showed that the five lysine mutations in the CT domain of VSV-G conferred resistance to MARCH8-mediated intracellular degradation ([Figure 1D](#fig1){ref-type="fig"}), whereas the two lysine mutations in the CT domain of HIV-1 Env had no effect on its cell-surface downregulation by MARCH8 ([Figure 1E](#fig1){ref-type="fig"}). It should be noted that MARCH8-resistant VSV-G CT5K/R colocalized with MARCH8 ([Figure 1D](#fig1){ref-type="fig"}). We thus speculated that MARCH8 ubiquitinates lysine residues of VSV-G but not of HIV-1 Env at their CT domains. Importantly, in the presence of MARCH8, HIV-1 Env preferentially colocalized with the trans-Golgi network (TGN) marker TGN46 ([Figure 1F](#fig1){ref-type="fig"}), consistent with our previous hypothesis that MARCH8 might sequester HIV-1 Env in the TGN without degradation ([@bib14]).

![MARCH8 targets and ubiquitinates cytoplasmic lysine residues of VSV-G but not of HIV-1 Env.\
(**A**) Schematic structure of the lysine mutants of VSV-G (CT5K/R; upper) and HIV-1 Env (CT2K/R; lower). SP, signal peptide; EC, extracellular domain; TM, transmembrane domain; CT, cytoplasmic tail; SU, surface subunit. (**B**) Infectivity of viruses prepared from 293T cells cotransfected with Env-defective HIV-1 luciferase (luc) reporter proviral DNA and either the VSV-G wild-type (WT) or CT5K/R mutant plasmid together with either a control (Ctrl) (black) or HA-MARCH8 (gray) plasmid. Data are shown as a percentage of the viral infectivity in the absence of MARCH8 when WT VSV-G was used (mean + s.d. from three independent experiments). (**C**) Infectivity of viruses prepared as shown in *B*, except for using either the WT HIV-1 Env or its CT2K/R mutant plasmid (mean + s.d. from three independent experiments). (**D**) The VSV-G lysine mutant is resistant to MARCH8-mediated intracellular degradation. Shown are immunofluorescence-based analyses of the intracellular expression of either the WT or CT5K/R mutant VSV-G with or without MARCH8 in transfected HOS cells. Scale bars, 10 μm. Note that the cell-staining for VSV-G cannot be performed because VSV-G is tagged with the T7 epitope (T7e) at the C-terminus. (**E**) The lysine mutant of HIV-1 Env is still sensitive to MARCH8-induced downregulation from the cell surface. Immunofluorescence images show cell-surface expression of either the WT or CT2K/R mutant HIV-1 Env with or without MARCH8 in transfected HOS cells. Scale bars, 10 μm. (**F**) MARCH8 sequesters HIV-1 Env in the trans-Golgi network (TGN). Immunofluorescence images show intracellular localization of either the WT or CT2K/R mutant HIV-1 Env and the TGN marker TGN46, with or without MARCH8 in transfected HOS cells. Scale bars, 10 μm. (**G**) Lysine residues at the CT domain of VSV-G are ubiquitinated by MARCH8. The ubiquitination of the WT or CT5K/R mutant VSV-G tagged with T7e in cells expressing control or MARCH8 (WT or RING-CH mutant (CS)) was examined by immunoprecipitation (IP) of either ubiquitinated proteins with an anti-ubiquitin antibody (left panel) or of T7e-tagged VSV-G with an anti-T7e antibody (right panel), followed by immunoblotting with an antibody to either T7e (left panel) or ubiquitin (right panel), respectively.](elife-57763-fig1){#fig1}

To investigate this possibility, we performed immunoprecipitation (IP)/western-based ubiquitination assays. In cells coexpressing WT HA-MARCH8, VSV-G was efficiently ubiquitinated, whereas in cells coexpressing the RING-CH mutant of HA-MARCH8, the ubiquitination of VSV-G was lost. More importantly, the VSV-G lysine mutant CT5K/R did not undergo MARCH8-mediated ubiquitination, as expected ([Figure 1G](#fig1){ref-type="fig"}), suggesting that the lysine residues at the CT domain of VSV-G are specifically ubiquitinated by MARCH8. These findings are consistent with the immunofluorescence results ([Figure 1D and E](#fig1){ref-type="fig"}). We therefore conclude that lysine residues at the CT domain of VSV-G are ubiquitinated by MARCH8, which determines the difference in the MARCH8-mediated intracellular fate between these viral glycoproteins.

Because unlike VSV-G, HIV-1 Env was retained intracellularly without degradation, as we previously reported ([@bib14]), we hypothesized that these viral envelope glycoproteins might undergo endocytosis with different mechanisms of action. It has been reported that another MARCH family member, MARCH11, has a conserved tyrosine-based motif, YXXϕ, which is known to be recognized by the adaptor protein (AP) μ-subunits in the C-terminal CT domain ([@bib12]). We therefore looked for the same motif(s) in MARCH8 and found the ^222^YxxL^225^ and ^232^YxxV^235^ sequences in the CT domain at the C-terminus ([Figure 2A](#fig2){ref-type="fig"}). Based on this finding, we generated tyrosine motif mutants of MARCH8, in which either ^222^Y or ^232^Y was mutated to alanine (designated ^222^AxxL^225^ or ^232^AxxV^235^). The protein expression in cells transfected with each MARCH8 plasmid was confirmed by immunoblotting using an anti-hemagglutinin (HA) antibody ([Figure 2B](#fig2){ref-type="fig"}). Then, we examined whether these YXXϕ motifs are important for the antiviral activity of MARCH8. The infectivity of VSV-G--pseudotyped viruses was still inhibited by the expression of both ^222^AxxL^225^ and ^232^AxxV^235^ MARCH8 mutants ([Figure 2C](#fig2){ref-type="fig"}). In contrast, the infectivity of HIV-1 Env--pseudotyped viruses was not impaired by ^222^AxxL^225^ MARCH8 expression but was reduced by that of ^232^AxxV^235^ and WT MARCH8 ([Figure 2D](#fig2){ref-type="fig"}), suggesting that the first tyrosine motif (^222^YxxL^225^) is involved in the antiviral activity of MARCH8 against HIV-1 Env but not VSV-G.

![The tyrosine motif of MARCH8 mediates downregulation of HIV-1 Env but not of VSV-G.\
(**A**) Schematic structure of YxxΦ motif mutants of MARCH8 (^222^YxxL^225^ and ^232^YxxV^235^). (**B**) Western blot analysis was performed by using extracts from 293T cells transfected with HA-tagged MARCH8 expression plasmids. Antibodies specific for HA were used to detect MARCH8 proteins. (**C, D**) Infectivity of viruses prepared from 293T cells cotransfected with Env-defective HIV-1 luciferase (luc) reporter proviral DNA and either a control (Ctrl), HA- WT, HA-^222^AxxL^225^ or HA-^232^AxxV^235^ MARCH8 plasmid, together with either (**C**) the VSV-G expression plasmid or (**D**) the HIV-1 Env expression plasmid. Data are shown as a percentage of the viral infectivity in the absence of MARCH8 (mean + s.d. from three independent experiments). ns; \*\*\*p\<0.0005 compared with the Ctrl using two-tailed unpaired *t*-tests. (**E, F**) BlaM-Vpr-based viral entry assay using VSV-G-pseudotyped viruses (**E**) or NL4-3 whole viruses (**F**) produced from cells expressing either control, WT MARCH8, or the ^222^AxxL^225^ mutant. Representative FACS dot plots are shown from four independent experiments. (**G**) VSV-G is downregulated by both WT and ^222^AxxL^225^ mutant MARCH8, (**H**) whereas the cell-surface expression of HIV-1 Env is not affected by the mutant MARCH8. (**I**) ^222^AxxL^225^ MARCH8 expression in producer cells is unable to decrease HIV-1 gp120 levels in viral supernatants. ELISA-based levels of Env gp120 in viral supernatants from 293T cells cotransfected with luc reporter proviral DNA and NL-Env plasmid, together with either MARCH8 WT or its ^222^AxxL^225^ mutant. Representative data from three independent experiments are shown as percent Env gp120/Gag p24 in the supernatants relative to that from control cells. (mean + s.d. from three independent experiments). ns; \*\*\*p\<0.0005 compared with the Ctrl using two-tailed unpaired *t*-tests.](elife-57763-fig2){#fig2}

We previously reported that the MARCH8-mediated reduction in viral infectivity was due to reduced entry efficiency, resulting from a decreased virion incorporation of envelope glycoproteins through their downregulation from the cell surface ([@bib14]). Therefore, by performing a β-lactamase (BlaM)-fused viral protein R (Vpr)-based entry assay, we first focused on whether the loss of function of ^222^AxxL^225^ MARCH8 against HIV-1 Env but not VSV-G would indeed be due to the loss of its inhibitory activity on viral entry. Whereas the entry of VSV-G--pseudotyped HIV-1 prepared from cells expressing either WT or ^222^AxxL^225^ MARCH8 was reduced compared with that of the control virus ([Figure 2E](#fig2){ref-type="fig"}), the inhibition of the entry of whole HIV-1 virions was abrogated in viruses produced from cells expressing ^222^AxxL^225^, as expected ([Figure 2F](#fig2){ref-type="fig"}). We further analyzed whether this motif of MARCH8 is indeed involved in the reduced virion incorporation of HIV-1 Env, which results from its cell-surface downregulation. To address this, we conducted flow cytometric analysis and quantified the levels of cell-surface and intracellular expression of Env glycoproteins. In accordance with the results obtained in infectivity assays ([Figure 2C](#fig2){ref-type="fig"}), ^222^AxxL^225^ MARCH8 still reduced intracellular VSV-G expression as well as WT MARCH8 did ([Figure 2G](#fig2){ref-type="fig"}). On the other hand, the mutant MARCH8 had a completely abrogated ability to downregulate cell-surface HIV-1 Env, whereas WT expression led to the downregulation of HIV-1 Env from the cell surface and its intracellular retention ([Figure 2H](#fig2){ref-type="fig"}), as we previously observed ([@bib18]). The results were consistent with those of the inhibitory activity of MARCH8 against the virion incorporation of HIV-1 Env ([Figure 2I](#fig2){ref-type="fig"}). We therefore conclude that ^222^YxxL^225^ is critical for the MARCH8-mediated downregulation of HIV-1 Env but not VSV-G, which results in its reduced virion incorporation leading to impaired viral entry.

In summary, we first show the two different mechanisms by which MARCH8 inhibits viral infections, one being a ubiquitin-dependent downregulation that mediates lysosomal degradation of VSV-G whose cytoplasmic lysine residues are recognized by the RING-CH domain of MARCH8 ([Figure 3](#fig3){ref-type="fig"}, left), and the other, a YxxΦ motif-dependent downregulation that could explain the intracellular retention of HIV-1 Env in the TGN without degradation after cell-surface downregulation ([Figure 3](#fig3){ref-type="fig"}, right). In terms of the latter mechanism, although this could be attributed to the AP-dependent trafficking that requires the YxxΦ motif, which binds to AP μ-subunits, our preliminary results were unable to show the interaction between these subunits and MARCH8, due to technical difficulties in detecting specific bands in our IP/western blotting assays. We have recently reported that MARCH1 and MARCH2 are also antiviral MARCH family members that inhibit HIV-1 infection, although their antiviral activity is less robust, which is probably due to the lower protein expression and/or stability than that of MARCH8 ([@bib18]). Because MARCH1 and MARCH2 also harbor the Yxxϕ motif in their C-terminal CT domains, it would be intriguing to verify the importance of the motif in these proteins. It should be noted that in this study, we tested either HIV-1 Env or VSV-G derived from a single representative strain, which is a limitation of our present findings. Nevertheless, the present findings are consistent with our previous studies showing that MARCH8-induced downregulation of VSV-G leads to lysosomal degradation, while that of HIV-1 Env results in intracellular retention without degradation. In this context, the reason why VSV infection in human is always subclinical ([@bib8]) could be explained at least in part by the observation that VSV-G is completely inactivated even by lower levels of MARCH8 ([@bib14]). Conversely, in the case of HIV-1 infection, it is intriguing to postulate that the virus might rather take advantage of infection of macrophages enriched with MARCH8 ([@bib14]; [@bib18]) as an ideal hideout, in which the virus could escape from immunosurveillance potentially due to the MARCH8-induced downregulation of Env from the cell surface. Overall, we conclude that MARCH8 targets HIV-1 Env and VSV-G by two different inhibitory mechanisms (either ubiquitin-dependent or YxxΦ motif-dependent downregulation). Further investigations will clarify the more detailed host defense mechanisms of this protein.

![Schematic diagram of two different molecular mechanisms by which MARCH8 inhibits viral infection.\
*Left*, MARCH8 (red) downregulates VSV-G (violet) in a ubiquitin-dependent manner. The RING-CH domain (pink) of MARCH8 recognizes VSV-G's cytoplasmic lysine residues, which results in ubiquitin conjugation (shown as orange beads), leading to lysosomal degradation; *Right*, MARCH8 downregulates HIV-1 Env (green) in a YxxΦ motif-dependent manner. The tyrosine motif located in the C-terminal CT of MARCH8 likely interacts with the adaptor protein μ-subunits (navy) (if this is the case with μ2 or μ1, clathrin (brown) is involved in this step), resulting in the intracellular retention of HIV-1 Env in the TGN without degradation. It should be noted that the downregulation of these viral glycoproteins might not necessarily occur at the plasma membrane. The nucleus and other organelles are not shown.](elife-57763-fig3){#fig3}

Materials and methods {#s3}
=====================

DNA constructs {#s3-1}
--------------

The Env-deficient HIV-1 proviral indicator construct pNL-Luc2-E(-), HIV-1 Gag-Pol expression plasmid pC-GagPol-RRE, HIV-1 Env-expression vector pC-NLenv, HIV-1 Rev expression plasmid pCa-Rev, VSV-G expression plasmid pC-VSVg and its C-terminally T7-epitope-tagged version pVSVg-T7E, GFP expression plasmid pCa-EGFP, Vpr/β-lactamase (BlaM) expression plasmid pMM310, and MARCH8 expression plasmid either pC-MARCH8 or pC-HA-MARCH8 and its RING-CH mutant pC-HA-MARCH8-CS have previously been described elsewhere ([@bib9]; [@bib14]). The HIV-1 Env gp41 mutant CT2K/R, in which cytoplasmic lysine residues at positions 792 and 806 were mutated to arginine, and the VSV-G mutant CT5K/R, in which cytoplasmic lysine residues at positions 491, 493, 496, 497, and 511 were mutated to arginine residues, were created by inserting overlapping PCR fragments into *Mfe*I/*Xho*I-digested pC-NLenv and by inserting PCR fragments into *Kpn*I/*Not*I-digested pC-VSVg (or pVSVg-T7E), respectively. The MARCH8 mutant ^222^AxxL^225^ or ^232^AxxV^235^, in which a tyrosine residue at position 222 or 232 was mutated to an alanine residue, was generated by inserting overlapping PCR fragments into the *Kpn*I/*Xho*I-digested pCAGGS or *Xho*I/*Not*I-digested pCAGGS-NHA to create an untagged or N-terminally HA-tagged expression plasmid. All constructs were verified by a DNA sequencing service (FASMAC).

Cell maintenance {#s3-2}
----------------

293T, MT4 (RRID:[CVCL_2632](https://scicrunch.org/resolver/CVCL_2632)), HeLa, MAGIC5 (HeLa derivative \[[@bib11]\]), and HOS cells were maintained under standard conditions. Cells were originally obtained from ATCC (except MAGIC5 cells) and routinely tested negative for mycoplasma contamination (PCR Mycoplasma Detection kit, Takara).

Viral infectivity assays {#s3-3}
------------------------

To prepare VSV-G-pseudotyped or HIV-1-Env-pseudotyped luciferase reporter viruses, 2.5 × 10^5^ 293T cells were cotransfected with 120 ng of either the MARCH expression plasmid (note that this DNA amount was previously optimized to reflect endogenous expression in macrophages) or a control plasmid, 20 ng of pC-VSVg, pC-VSVg-CT5K/R, pC-NLenv, or pC-NLenv-CT2K/R, 500 ng of pNL-Luc2-E(-), and an empty vector up to 1 μg of total DNA, using FuGENE 6 (Promega). Sixteen hours later, the cells were washed with phosphate-buffered saline (PBS), and 1 ml of fresh complete medium was added. After 24 hr, supernatants were treated as described above and then harvested. The p24 antigen levels in viral supernatants were measured by an HIV-1 p24 antigen capture ELISA (XpressBio). To determine viral infectivity, 1 × 10^4^ MAGIC5 cells were incubated with 1 ng of p24 antigen from the HIV-1 supernatants. After 48 hr, cells were lysed in 100 μl of One-Glo Luciferase Assay Reagent (Promega). The firefly luciferase activity was determined with a Centro LB960 (Berthold) luminometer.

Immunoblotting assays {#s3-4}
---------------------

Protein expression of constructs was confirmed by western blot analyses as described elsewhere ([@bib14]; [@bib18]). Briefly, cells transfected as described above were lysed in 500 μl of lysis buffer containing 1.25% n-octyl-β-D-glucoside (Dojindo), and Complete protease inhibitor cocktail (Roche Applied Science). Cell extracts were then subjected to gel electrophoresis and transferred to a nitrocellulose membrane, followed by probing with an anti-HA mouse monoclonal antibody (Sigma-Aldrich, H9658) or an anti-β-actin mouse monoclonal antibody (Sigma-Aldrich, A5316). Proteins were then visualized by chemiluminescence using an ECL western blotting detection system (GE Healthcare) and monitored by using a LAS-3000 imaging system (FujiFilm).

Viral entry assays {#s3-5}
------------------

A β-lactamase (BlaM)-fused viral protein R (Vpr)-based entry assay was performed as described elsewhere ([@bib14]; [@bib18]). Briefly, HIV-1 particles containing a fusion protein of BlaM-Vpr were produced by cotransfection of 293 T cells (5 X 10^5^) with 1 μg of pNL4-3 ([@bib1]), 300 ng of pMM310 ([@bib15]) encoding BlaM-Vpr, 240 ng of either the control vector, pC-MARCH8, pC-MARCH8-^222^AxxL^225^ or pC-MARCH8-^232^AxxV^235^, and the control vector up to 1 μg of total DNA. Similarly, VSV-G-pseudotyped HIV-1 particles containing BlaM-Vpr were prepared by cotransfection with 1 μg of pNL-E(-) ([@bib9]), 40 ng of pC-VSVg, 300 ng of pMM310, 240 ng of either the control vector, pC-MARCH8, pC-MARCH8-^222^AxxL^225^, pC-MARCH8-^232^AxxV^235^, and or the control vector up to 1 μg of total DNA. The produced viruses were normalized to the p24 antigen level (100 ng) and used for infection of the CD4^+^ T cell line MT4 (5 × 10^5^ cells) at 37°C for 4 hr to allow viral entry. After extensive washing with Hank\'s balanced salt solution (HBSS; Invitrogen), cells were incubated with 1 μM CCF2-AM dye (Invitrogen), a fluorescent substrate of BlaM, in HBSS containing 1 mg ml^--1^ Pluronic F-127 surfactant (Invitrogen) and 0.001% acetic acid for 1 hr at room temperature and then washed with HBSS. Cells were further incubated for 14 hr at room temperature in HBSS supplemented with 10% FBS, washed three times with PBS and fixed in a 1.2% paraformaldehyde solution. Fluorescence was monitored at 520 and 447 nm by flow cytometry using BD FACS Canto II (BD Bioscience), and the data were collected and analyzed with BD FACS Diva Software (BD Bioscience).

Flow cytometry {#s3-6}
--------------

293T cells (5 × 10^5^) were cotransfected with 0.8 µg of either the control vector and 200 ng of pCa-EGFP, or the combination of 120 ng of either the MARCH expression plasmid (WT or a tyrosine mutant) or the control vector, 20 ng of either pC-VSVg or pC-NLenv, 500 ng of pNL-Luc2-E(-), and the control vector up to 1 μg. To analyze cell-surface expression, the transfected cells were incubated with either anti-HIV-1 gp120 goat polyclonal antibody (Abcam, ab21179) or anti-VSV-G mouse monoclonal antibody (Sigma-Aldrich, V5507), followed by staining for 30 min on ice with either a rabbit anti-goat IgG conjugated with Alexa 647 (Molecular Probes, A21446) or a goat anti-mouse IgG conjugated with R-phycoerythrin (Molecular Probes P-852), respectively. Cells were washed extensively with PBS with 4% FBS and fixed with 4% formaldehyde in PBS. To analyze intracellular expression, the transfected cells were fixed with 0.01% formaldehyde in PBS, permeabilized with 0.05% saponin for 10 min, and immunostained with the antibody against either gp120 or VSV-G, followed by incubation with secondary antibodies, as described above. GFP-positive cells were sorted and analyzed for the expression of HIV-1 Env or VSV-G by flow cytometry using a BD FACS Canto II, and the data were collected and analyzed with BD FACS Diva Software.

Env incorporation assays {#s3-7}
------------------------

HIV-1 gp120 ELISA-based Env incorporation assays were performed by using an HIV-1 gp120 antigen capture ELISA kit (Advanced BioScience Laboratories), according to the manufacturer's instructions. To normalize Env levels in viral supernatants, p24 antigen was measured by the HIV-1 p24 antigen capture ELISA.

Ubiquitination assays {#s3-8}
---------------------

293T cells (5 × 10^5^) were cotransfected with 0.8 μg of pC-VSVg-T7E, 0.4 μg of the control vector, and 0.8 μg of either the control vector, pC-HA-MARCH8, or pC-HA-MARCH8-CS. After 48 hr, cells were lysed in TBS-T buffer (50 mM Tris-HCl buffer (pH 7.5), 0.15 M NaCl, 1% Triton X-100, and 0.5% deoxycholic acid) containing a protease inhibitor cocktail and 10 mM N-ethylmaleimide, as an inhibitor of deubiquitination enzymes. The mixture was centrifuged at 21,500 × g for 15 min, and the supernatant was used as total cell lysate for immunoblotting or IP. Fifty microliters of Protein A-coupled Sepharose 4B (GE Healthcare, 17-0780-01) was preincubated for 2 hr at 4°C with 4 μg of the appropriate antibody (anti-T7 epitope rabbit polyclonal antibody, MBL, PM022; anti-ubiquitin mouse monoclonal antibody Clone FK2, Cayman, 14220). Total cell lysate was incubated with antibody-coupled Sepharose for 20 hr at 4°C. The Sepharose was washed three times with TBS-T buffer and one time with PBS before the immunoprecipitated proteins were eluted with SDS sample buffer. To evaluate the ubiquitination states of the immunoprecipitated proteins, proteins immunoprecipitated with an anti-T7 epitope rabbit antibody were subjected to western blotting with an anti-ubiquitin mouse antibody, whereas proteins immunoprecipitated with the anti-ubiquitin mouse antibody were subjected to western blotting with the anti-T7 epitope rabbit antibody. Immunoreactive bands were detected using an ECL detection kit (EzWestLumi plus, ATTO) with a ChemiDoc imaging system (Bio-Rad).

Immunofluorescence microscopy {#s3-9}
-----------------------------

HOS cells were plated on 13 mm coverslips, cotransfected with the indicated plasmids, 0.5 μg of either pC-NLenv (WT or CT2K/R) or pC-VSVg-T7E (WT or CT5K/R), 0.1 μg of pC-Gag-Pol, 0.05 μg of pCa-Rev, and 0.3 μg of either pC-HA-MARCH8 expression plasmid or a control plasmid using FuGENE6 and cultured for 24 hr. For the total staining of VSV-G and MARCH8, cells were fixed with 4% paraformaldehyde for 30 min on ice and permeabilized with 0.05% saponin (Sigma-Aldrich). The fixed cells were incubated with primary antibodies, anti-T7 epitope mouse monoclonal antibody (Novagen, 69522--4) and anti-HA goat polyclonal antibody (GenScript, A00168-40). The secondary antibodies, Alexa 488 donkey anti-mouse IgG (Molecular Probes, A-21202) and Alexa 647 donkey anti-goat IgG (Molecular Probes, A-21447) were used for the double staining assay. For the cell surface staining of gp120 protein, cells were incubated with an anti-gp120 mouse monoclonal antibody (0.5β [@bib10]; kindly provided by S. Matsushita) at 4°C for 5 min and washed with PBS at 4°C before fixation. Fixation was performed with 4% paraformaldehyde for 30 min on ice, and fixed cells were permeabilized with 0.05% saponin to detect the intracellular expression and localization of MARCH8 proteins. The coverslips were incubated with the anti-HA rabbit polyclonal antibody (Sigma Aldrich, H6908) for 1 hr, washed with PBS and incubated for 30 min with the secondary antibodies Alexa 488 donkey anti-mouse IgG (Molecular Probes, A-21202) and Alexa 647 donkey anti-rabbit IgG (Molecular Probes, A-31573) for the double staining assay. For the total staining of gp120, MARCH8, and TGN46 (as a trans-Golgi network (TGN) marker), the fixed cells were incubated with primary antibodies, anti-HIV-1 gp120 goat polyclonal antibody (Abcam, ab21179), anti-HA mouse monoclonal antibody (Sigma Aldrich, H3663), and anti-TGN46 rabbit polyclonal antibody (Abcam, ab50595) for 1 hr, washed with PBS and followed by the incubation for 30 min with the secondary antibodies, Alexa 488 donkey anti-goat IgG (Molecular Probes, A-11055), Alexa 568 donkey anti-rabbit IgG (Molecular Probes, A-10042) and Alexa 647 donkey anti-mouse IgG (Molecular Probes, A-31571) for the triple staining. Confocal images were obtained with a FluoView FV10i automated confocal laser-scanning microscope (Olympus; Tokyo).

Statistical analyses {#s3-10}
--------------------

Column graphs that combine bars and individual data points were created with GraphPad Prism version 8.04. *P*-values generated from two-tailed unpaired *t*-tests for data represented in [Figures 2C, D and I](#fig2){ref-type="fig"}.
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###### Source data for [Figure 1G](#fig1){ref-type="fig"} and [2B](#fig2){ref-type="fig"}.

Original uncropped images of IP-western blot (ubiquitination assays) in [Figure 1G](#fig1){ref-type="fig"}. The PVDF membranes were incubated with an anti-T7-epitope tag antibody, or with an anti-ubiquitin antibody. Images shown in [Figure 1G](#fig1){ref-type="fig"} were cropped from the boxed areas, and the brightness/contrast was adjusted equally across the entire image using Photoshop CS6 [Figure 2B](#fig2){ref-type="fig"} source data. Original uncropped images of western blot in [Figure 2B](#fig2){ref-type="fig"}. The PVDF membrane was incubated with an anti-HA antibody, then stripped and reprobed with an anti-β-actin antibody for a loading control. Images shown in [Figure 2B](#fig2){ref-type="fig"} were cropped from the boxed areas, and the brightness/contrast was adjusted equally across the entire image using Photoshop CS6.
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  Reagent type (species) or resource   Designation                                            Source or reference                Identifiers                                                                   Additional information
  ------------------------------------ ------------------------------------------------------ ---------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  Gene(*Homo sapiens*)                 MARCH8                                                 NCBI                               BC025394                                                                      
  Recombinant DNA reagent              pNL4-3                                                 [@bib1]                                                                                                          
  Recombinant DNA reagent              pNL-E(-)                                               [@bib9]                                                                                                          
  Recombinant DNA reagent              pNL-Luc2-E(-)                                          [@bib14]                                                                                                         
  Recombinant DNA reagent              pC-GagPol-RRE                                          [@bib14]                                                                                                         
  Recombinant DNA reagent              pC-NLenv                                               [@bib14]                                                                                                         
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The study reports differences in the mechanism of antiviral activity of the cellular protein MARCH8 on two different viruses, HIV and VSV. The study demonstrates that while MARCH8 downregulates the envelope protein of HIV, it does not degrade this HIV protein. This is in contrast to VSV-G, where MARCH8 downregulates the viral envelope protein and degrades it. The study illustrates a differential mechanisms of antiviral inhibition for the same host protein with different viruses.

**Decision letter after peer review:**

Thank you for submitting your article \"MARCH8 inhibits viral infection by two different mechanisms\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Päivi Ojala as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is \"in revision at *eLife*\". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

This manuscript follows earlier findings (Tada et al., 2015) in which they identified MARCH8 as a novel antiviral factor that inhibited VSV-G and HIV-1 Envelope to differing degrees. In the present manuscript, the authors revisit the antiviral activity of MARCH8, which has been found to downregulate several cellular transmembrane proteins. In this study the authors show that MARCH8 reduces cell surface Envelope via two pathways: ubiquitination and internalization via tyrosine motif. They show through viral entry, ubiquitination, and immunofluorescence assays that MARCH8 inhibits VSV-G through ubiquitination of its lysine residues, whereas HIV-1 is inhibited by MARCH8 through a conserved cytoplasmic tyrosine motif critical for intracellular protein sorting. This study suggest that the conserved antiviral function of MARCH8 is mediated by different mechanisms for these two viruses.

Summary:

The study of Zhang et al. reports differences in the mechanism of MARCH8 antiviral effects on HIV versus VSV-G. The study follows from a 2015 Nature Medicine paper showing that MARCH8 inhibits HIV replication by reducing the levels of Env on the cell and virus surface. The present study extends this work to show that while MARCH8 downregulates HIV Env, it does not degrade ENV. This is in contrast to VSV-G, where MARCH8 downregulates the viral protein and degrades it. They show evidence that the viral envelope proteins might undergo endocytosis differently, one being ubiquitin dependent the other dependent on a tyrosine motif. The study illustrates a differential mechanisms of antiviral inhibition for the same host protein with different viruses.

Essential revisions:

The authors conclude that VSV-G and HIV Env are targeted by two mechanisms of MARCH8 that are substantially different. This conclusion would be strengthened and the impact of the manuscript would be increased if the authors provided a better mechanistic understanding of how March 8 affects the two viral proteins differently. The major conclusions do require a modest amount of additional new data to be fully supported. The major conclusion of this publication is that MARCH8 reduces cell-surface and virion incorporation of HIV-1 Envelope. In contrast, MARCH8 downregulates VSV glycoprotein from cell-surface and degrades it via ubiquitin-mediated degradation. The mechanistic details behind the fate of HIV-1 Envelope are lacking. Since the substantive claim of the manuscript is the distinctive mechanism(s) by which MARCH8 exhibits its antiviral effects on HIV-1 and VSV -- it is necessary that at least the following comment be addressed:

The loss of cell surface localization of HIV-1 Envelope upon MARCH8 overexpression is striking. However, as presented, the details regarding intracellular retention of HIV-1 Env are not clear. This is an essential claim of this study and thus it is recommended that microscopy experiments be performed to elucidate this mechanism: where is HIV-1 Env being sorted? This can be easily done by performing colocalization staining with known intracellular compartment markers.

Overall, the mechanism by which MARCH-8 internalizes HIV Env is under-developed. The observation that the tyrosine at position 222 is required is interesting. It is tempting to speculate that one or more AP complexes are involved, but the authors state their preliminary data, which they do not show, does not support this hypothesis. Despite this, in their model they still speculate that AP complexes are involved. The contradictory statements are very confusing.

The authors also need to explain how the levels of MARCH8 expression levels in their system compare to endogenous levels in HIV target cells. Over expression studies are notorious for artifacts and if the levels are higher, this must be noted.
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Author response

> Essential revisions:
>
> The authors conclude that VSV-G and HIV Env are targeted by two mechanisms of MARCH8 that are substantially different. This conclusion would be strengthened and the impact of the manuscript would be increased if the authors provided a better mechanistic understanding of how March 8 affects the two viral proteins differently. The major conclusions do require a modest amount of additional new data to be fully supported. The major conclusion of this publication is that MARCH8 reduces cell-surface and virion incorporation of HIV-1 Envelope. In contrast, MARCH8 downregulates VSV glycoprotein from cell-surface and degrades it via ubiquitin-mediated degradation. The mechanistic details behind the fate of HIV-1 Envelope are lacking. Since the substantive claim of the manuscript is the distinctive mechanism(s) by which MARCH8 exhibits its antiviral effects on HIV-1 and VSV -- it is necessary that at least the following comment be addressed:
>
> The loss of cell surface localization of HIV-1 Envelope upon MARCH8 overexpression is striking. However, as presented, the details regarding intracellular retention of HIV-1 Env are not clear. This is an essential claim of this study and thus it is recommended that microscopy experiments be performed to elucidate this mechanism: where is HIV-1 Env being sorted? This can be easily done by performing colocalization staining with known intracellular compartment markers.

We appreciate the reviewer's comments. As suggested, we performed colocalization staining by using an antibody against the trans-Golgi network (TGN) marker TGN46, and found that in the presence of MARCH8, HIV-1 Env preferentially colocalized with TGN46, suggesting that MARCH8 can sequester HIV-1 Env in the TGN without degradation, as we previously hypothesized. We have added the data in Figure 1F, and the related text in the first paragraph of the Results and Discussion.

> Overall, the mechanism by which MARCH-8 internalizes HIV Env is under-developed. The observation that the tyrosine at position 222 is required is interesting. It is tempting to speculate that one or more AP complexes are involved, but the authors state their preliminary data, which they do not show, does not support this hypothesis. Despite this, in their model they still speculate that AP complexes are involved. The contradictory statements are very confusing.

We thank the reviewer for this point. We apologize for the confusion caused by our statements concerning the possible binding of MARCH8's YxxΦ motif with AP μ-subunits, which sound contradictory. The reason why we could not see the interaction between AP μ-subunits and MARCH8 in our preliminary data was not based on the results obtained under established conditions, but rather based on those due to the technical difficulties in detecting specific bands in our IP/Western blotting assays. We have therefore amended the related text in the last paragraph of the Results and Discussion.

> The authors also need to explain how the levels of MARCH8 expression levels in their system compare to endogenous levels in HIV target cells. Over expression studies are notorious for artifacts and if the levels are higher, this must be noted.

In our previous paper (Tada et al., 2015), by performing real-time RT-PCR, we optimized DNA amounts of MARCH8 expression plasmid (120 ng/a total of 1 μg) for transfection into 293T cells, based on the endogenous mRNA levels of expression in macrophages that express higher levels of MARCH8 mRNA. Here in this study, we used an aforementioned optimized amount of MARCH8 plasmid for transfection of 293T cells throughout the experiments. We have added the related text in the Materials and methods section (subsection "Viral infectivity assays").
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